Aikyo Tatsuki, Kogetsu Atsushi, Kato Kazuto
Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Osaka, Japan.
Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Asian Bioeth Rev. 2023 Apr 26;15(4):431-455. doi: 10.1007/s41649-023-00251-8. eCollection 2023 Oct.
Genome editing is a technology that can accurately and efficiently modify the genome of organisms, including the human genome. Although human genome editing (HGE) has many benefits, it also involves technical risks and ethical, legal, and social issues. Thus, the pros and cons of using this technology have been actively debated since 2015. Notably, the research community has taken an interest in the issue and has discussed it internationally. However, for the governance of HGE, the roles of government agencies and the general public are also important for an effective regulatory system. Here, we examine the roles of the research community, government, and public in the governance of HGE through an analysis of discussions in the Japanese Expert Panel on Bioethics. During the discussion of the research ethics review system, the professionalism of the research community and the pros and cons of state oversight have become issues for debate. Furthermore, through an examination of the overall policy-making process, three stakeholders are clearly involved in the governance of emerging medical technologies in the Expert Panel on Bioethics, a discussion forum established by government agencies. The contrast among these roles provides insight into the positive roles of government agencies and the research community and the conditions under which these roles are played. We also note that there are diverse actors in the public, which may have an impact on their participation. Our results may serve as a guide for countries and organizations to establish governance on emerging medical technologies.
基因组编辑是一种能够准确且高效地修饰生物体基因组(包括人类基因组)的技术。尽管人类基因组编辑(HGE)有诸多益处,但它也涉及技术风险以及伦理、法律和社会问题。因此,自2015年以来,关于使用这项技术的利弊一直存在激烈争论。值得注意的是,研究界对该问题产生了兴趣并在国际上进行了讨论。然而,对于人类基因组编辑的治理而言,政府机构和公众的作用对于有效的监管体系也很重要。在此,我们通过分析日本生物伦理专家小组的讨论,审视研究界、政府和公众在人类基因组编辑治理中的作用。在讨论研究伦理审查体系时,研究界的专业性以及国家监管的利弊已成为争论焦点。此外,通过审视整个决策过程,在政府机构设立的讨论论坛——生物伦理专家小组中,三个利益相关者明显参与了新兴医疗技术的治理。这些角色之间的对比为洞察政府机构和研究界的积极作用以及发挥这些作用的条件提供了思路。我们还注意到公众中有不同的行为主体,这可能会对他们的参与产生影响。我们的研究结果可为各国及各组织建立新兴医疗技术治理机制提供参考。